82 related articles for article (PubMed ID: 7602375)
21. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
22. Treatment of acute non-lymphocytic leukemia with alternating non-cross resistant chemotherapy.
Kyo T; Dohy H
Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1641-52. PubMed ID: 3247827
[No Abstract] [Full Text] [Related]
23. Cures of leukemia with aggressive postremission treatment: an update of timed sequential therapy (Ac-D-Ac).
Burke PJ; Karp JE; Geller RB; Vaughan WP
Leukemia; 1989 Oct; 3(10):692-4. PubMed ID: 2674562
[TBL] [Abstract][Full Text] [Related]
24. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
[TBL] [Abstract][Full Text] [Related]
25. The treatment of acute granulocytic leukemia in adults.
Rosenthal DS; Moloney WC
N Engl J Med; 1972 Jun; 286(22):1176-8. PubMed ID: 4502490
[No Abstract] [Full Text] [Related]
26. Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation.
Champlin R; Ho W; Winston D; Decker R; Greenberg P; Burnison M; Holly FE; Gale RP
Semin Oncol; 1987 Jun; 14(2 Suppl 1):1-6. PubMed ID: 2438775
[No Abstract] [Full Text] [Related]
27. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Vogler WR; Velez-Garcia E; Omura G; Raney M
Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
[No Abstract] [Full Text] [Related]
28. [Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia].
Bian SG; Hao YS; Wang ZC
Zhonghua Nei Ke Za Zhi; 1990 Jan; 29(1):22-5, 60. PubMed ID: 2401166
[TBL] [Abstract][Full Text] [Related]
29. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
30. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Holowiecki J; Grosicki S; Giebel S; Robak T; Kyrcz-Krzemien S; Kuliczkowski K; Skotnicki AB; Hellmann A; Sulek K; Dmoszynska A; Kloczko J; Jedrzejczak WW; Zdziarska B; Warzocha K; Zawilska K; Komarnicki M; Kielbinski M; Piatkowska-Jakubas B; Wierzbowska A; Wach M; Haus O
J Clin Oncol; 2012 Jul; 30(20):2441-8. PubMed ID: 22508825
[TBL] [Abstract][Full Text] [Related]
31. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
32. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
33. Cytarabine dose for acute myeloid leukemia.
Löwenberg B; Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Ferrant A; Sonneveld P; Biemond BJ; Gratwohl A; de Greef GE; Verdonck LF; Schaafsma MR; Gregor M; Theobald M; Schanz U; Maertens J; Ossenkoppele GJ;
N Engl J Med; 2011 Mar; 364(11):1027-36. PubMed ID: 21410371
[TBL] [Abstract][Full Text] [Related]
34. Posttransfusion hepatitis in acute myelogenous leukemia. Effect on survival.
Foon KA; Yale C; Clodfelter K; Gale RP
JAMA; 1980 Oct; 244(16):1806-7. PubMed ID: 6932517
[TBL] [Abstract][Full Text] [Related]
35. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Tilly H; Castaigne S; Bordessoule D; Casassus P; Le Prisé PY; Tertian G; Desablens B; Henry-Amar M; Degos L
J Clin Oncol; 1990 Feb; 8(2):272-9. PubMed ID: 2299370
[TBL] [Abstract][Full Text] [Related]
36. [Cure of acute myeloblastic leukemia in a child with Down syndrome and tetralogy of Fallot].
Balcar-Boroń A; Nowaczyk-Michalak A; Graduszewska-Czerebiej K
Wiad Lek; 1992 Mar; 45(5-6):220-3. PubMed ID: 1455866
[No Abstract] [Full Text] [Related]
37. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Stone RM; Mazzola E; Neuberg D; Allen SL; Pigneux A; Stuart RK; Wetzler M; Rizzieri D; Erba HP; Damon L; Jang JH; Tallman MS; Warzocha K; Masszi T; Sekeres MA; Egyed M; Horst HA; Selleslag D; Solomon SR; Venugopal P; Lundberg AS; Powell B
J Clin Oncol; 2015 Apr; 33(11):1252-7. PubMed ID: 25732165
[TBL] [Abstract][Full Text] [Related]
38. Therapy of acute myelogenous leukemia: results of combination chemotherapy with cytarabine, daunorubicin and 6-mercaptopurine.
Ko WS; Chen LM; Hwang SH; Chao TY; Wang CC; Kao WY; Lee WC; Hwang WS
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Sep; 48(3):185-9. PubMed ID: 1657335
[TBL] [Abstract][Full Text] [Related]
39. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study.
Ravindranath Y; Steuber CP; Krischer J; Civin CI; Ducore J; Vega R; Pitel P; Inoue S; Bleher E; Sexauer C
J Clin Oncol; 1991 Apr; 9(4):572-80. PubMed ID: 2066754
[TBL] [Abstract][Full Text] [Related]
40. [Acute myelogenous leukemia in elderly patients].
Mori M
Nihon Ronen Igakkai Zasshi; 2000 Mar; 37(3):192-6. PubMed ID: 10879065
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
